Safety of Bevacizumab in Patients with Metastatic Breast Cancer

Treatment-Related Mortality With Bevacizumab in Cancer Patients

(2011) Vishal Ranpura et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients

(2010) I. E. Smith et al.   ANNALS OF ONCOLOGY

Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery?

(2010) M. Golshan et al.   ANNALS OF SURGICAL ONCOLOGY

Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer

(2010) Valentina Guarneri et al.   BREAST CANCER RESEARCH AND TREATMENT

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.

(2010) A. Brufsky et al.   CANCER RESEARCH

Phase III Studies of Bevacizumab (B) in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC): Summary of Selected Adverse Events.

(2010) N. Robert et al.   CANCER RESEARCH

Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.

(2010) LY Dirix et al.   CANCER RESEARCH

469 Incidence of selected adverse events (AEs) in phase III studies of bevacizumab (BV) in combination with chemotherapy for the treatment of HER2-negative metastatic breast cancer (mBC)

(2010) D.W. Miles et al.   EJC SUPPLEMENTS

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials

(2010) David Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients

(2010) S. Wu et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Intricacies of Bevacizumab-Induced Toxicities and Their Management

(2009) Sarah M Gressett et al.   ANNALS OF PHARMACOTHERAPY

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Bevacizumab Safety in Patients with Central Nervous System Metastases

(2009) B. Besse et al.   CLINICAL CANCER RESEARCH

Biological mechanisms of bevacizumab-associated adverse events

(2009) Gerald M Higa et al.   Expert Review of Anticancer Therapy

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

(2009) Robert Gray et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adverse effects of anticancer agents that target the VEGF pathway

(2009) Helen X. Chen et al.   Nature Reviews Clinical Oncology

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of anticoagulation use and bevacizumab in patients with glioma

(2008) Phioanh (Leia) Nghiemphu et al.   NEURO-ONCOLOGY

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE